General Anesthesia; Tracheal IntubationPhase 4NCT07597564
Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation
A Phase 4 study testing Metoprolol (MET), Sufentanil and Normal Saline (0.9% NaCl) in people with General Anesthesia; Tracheal Intubation, run by Fujian Provincial Hospital at 1 site in China.
Trial summary
This randomized, double-blind, controlled clinical study will evaluate the effects of different dose combinations of intravenous metoprolol and sufentanil on cardiovascular responses during oral endotracheal intubation under general anesthesia. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- General Anesthesia; Tracheal Intubation
- What is being tested?
- Metoprolol (MET), Sufentanil and Normal Saline (0.9% NaCl)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 900 participants
- Where
- 1 siteChina
- Study dates
- 22 Jun 2026to 22 May 2027
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 to 65 years.
- American Society of Anesthesiologists physical status I or II.
- Scheduled for elective non-cardiac surgery.
- Planned general anaesthesia with endotracheal intubation.
Who cannot join
- Cardiovascular or respiratory diseases, such as uncontrolled hypertension or bronchial asthma.
- Current use of β-blockers.
- History of chronic drug use or alcohol abuse.
- Hepatic or renal impairment.
- Known allergy to any study drug.
- Anticipated difficult airway.
- Any other condition that may affect the conduct of the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Fujian provincial hospital
Fuzhou, Fujian, 350000
Yanhua Guo, +86-18050333902, guoyanhua19@126.com
About this study
Official title: Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation: Prospective Randomized Double-blind Study
This randomized, double-blind, controlled clinical study will evaluate the effects of different dose combinations of intravenous metoprolol and sufentanil on cardiovascular responses during oral endotracheal intubation under general anesthesia.
Endotracheal intubation may cause transient increases in heart rate and blood pressure due to sympathetic stimulation. This study aims to determine whether metoprolol, in combination with different doses of sufentanil, can improve hemodynamic stability during and after intubation.
Read more
A total of 900 adult patients aged 18 to 65 years with American Society of Anesthesiologists physical status I or II who are scheduled for elective non-cardiac surgery under general anesthesia with endotracheal intubation will be enrolled. Participants will be randomly assigned to one of 30 groups according to the combination of metoprolol dose and sufentanil dose. Metoprolol doses include 0, 0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg, and sufentanil doses include 0.1, 0.2, 0.3, 0.4, and 0.5 mcg/kg.
All participants will receive standardized anesthetic induction and maintenance. Hemodynamic changes will be observed for 10 minutes after intubation. The main outcome is the success rate of hemodynamic stability within 0 to 10 minutes after intubation. Secondary outcomes include the incidence of hypotension, hypertension, bradycardia, and tachycardia.
- Conditions
- General Anesthesia; Tracheal Intubation
- Being tested
- Metoprolol (MET), Sufentanil, Normal Saline (0.9% NaCl)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Metoprolol (MET)Drug
Metoprolol will be administered intravenously before anesthetic induction at the assigned dose of 0, 0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg. The study drug will be given through a dedicated intravenous catheter, and each participant will receive the dose according to the randomized treatment arm.
SufentanilDrug
Sufentanil will be administered intravenously during anesthetic induction at the assigned dose of 0.1, 0.2, 0.3, 0.4, or 0.5 mcg/kg. Each participant will receive sufentanil in combination with the assigned metoprolol dose according to the randomized treatment arm.
Normal Saline (0.9% NaCl)Drug
Normal saline (0.9% NaCl) will be administered intravenously before anesthetic induction as placebo in a volume matched to the metoprolol intervention. The study drug will be delivered through a dedicated intravenous catheter, and participants assigned to the placebo arm will receive a volume corresponding to the randomized dosing schedule used in the metoprolol groups.
| Study group | Role | What they receive |
|---|---|---|
| Metoprolol 0 mg/kg + Sufentanil 0.1 mcg/kg | Active comparator | Not described Receives: Drug: Sufentanil; Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0 mg/kg + Sufentanil 0.2 mcg/kg | Active comparator | Not described Receives: Drug: Sufentanil; Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0 mg/kg + Sufentanil 0.3 mcg/kg | Active comparator | Not described Receives: Drug: Sufentanil; Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0 mg/kg + Sufentanil 0.4 mcg/kg | Active comparator | Not described Receives: Drug: Sufentanil; Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0 mg/kg + Sufentanil 0.5 mcg/kg | Active comparator | Not described Receives: Drug: Sufentanil; Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0.1 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.1 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.1 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.1 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.1 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Not described Receives: Drug: Metoprolol (MET); Drug: Sufentanil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants achieving hemodynamic stability after tracheal intubation
Measured: within 0-10 min after intubation
Secondary outcomes (4)
incidence of bradycardia
Measured: within 0-10 min after intubation
incidence of tachycardia
Measured: within 0-10 min after intubation
incidence of hypotension
Measured: within 0-10 min after intubation
incidence of hypertension
Measured: within 0-10 min after intubation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2026
- Study start22 Jun 2026 (estimated)
- Primary completion22 May 2027 (estimated)
- Study completion22 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for General Anesthesia; Tracheal IntubationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fujian Provincial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yanhua Guo, Fujian Provincial Hospital
- Investigators
- Yanhua Guo, Principal investigator, Fujian Provincial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07597564
- Sponsor's protocol ID
- K2024-03-015/02
- Status last verified
- May 2026
- First submitted
- 13 May 2026
- Last updated
- 20 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation: Prospective Randomized Double-blind Study
- ClinicalTrials.gov ID
- NCT07597564
- Acronym / sponsor ID
- K2024-03-015/02
- Conditions
- General Anesthesia; Tracheal Intubation
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 900 participants (estimated)
- Lead sponsor
- Fujian Provincial HospitalUniversity, hospital or other
- Study start
- 22 Jun 2026 (estimated)
- Primary completion
- 22 May 2027 (estimated)
- Study completion
- 22 May 2027 (estimated)
- First posted
- 19 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, double-blind, controlled clinical study will evaluate the effects of different dose combinations of intravenous metoprolol and sufentanil on cardiovascular responses during oral endotracheal intubation under general anesthesia.
Endotracheal intubation may cause transient increases in heart rate and blood pressure due to sympathetic stimulation. This study aims to determine whether metoprolol, in combination with different doses of sufentanil, can improve hemodynamic stability during and after intubation.
A total of 900 adult patients aged 18 to 65 years with American Society of Anesthesiologists physical status I or II who are scheduled for elective non-cardiac surgery under general anesthesia with endotracheal intubation will be enrolled. Participants will be randomly assigned to one of 30 groups according to the combination of metoprolol dose and sufentanil dose. Metoprolol doses include 0, 0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg, and sufentanil doses include 0.1, 0.2, 0.3, 0.4, and 0.5 mcg/kg.
All participants will receive standardized anesthetic induction and maintenance. Hemodynamic changes will be observed for 10 minutes after intubation. The main outcome is the success rate of hemodynamic stability within 0 to 10 minutes after intubation. Secondary outcomes include the incidence of hypotension, hypertension, bradycardia, and tachycardia.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 30
| Arm | Type | Receives |
|---|---|---|
| Metoprolol 0 mg/kg + Sufentanil 0.1 mcg/kg | Active comparator | Drug: Sufentanil, Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0 mg/kg + Sufentanil 0.2 mcg/kg | Active comparator | Drug: Sufentanil, Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0 mg/kg + Sufentanil 0.3 mcg/kg | Active comparator | Drug: Sufentanil, Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0 mg/kg + Sufentanil 0.4 mcg/kg | Active comparator | Drug: Sufentanil, Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0 mg/kg + Sufentanil 0.5 mcg/kg | Active comparator | Drug: Sufentanil, Drug: Normal Saline (0.9% NaCl) |
| Metoprolol 0.1 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.1 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.1 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.1 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.1 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.2 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.3 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.4 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.1 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.2 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.3 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.4 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
| Metoprolol 0.5 mg/kg + Sufentanil 0.5 mcg/kg | Experimental | Drug: Metoprolol (MET), Drug: Sufentanil |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age 18 to 65 years.
- American Society of Anesthesiologists physical status I or II.
- Scheduled for elective non-cardiac surgery.
- Planned general anaesthesia with endotracheal intubation.
Key exclusion criteria (7 listed)
- Cardiovascular or respiratory diseases, such as uncontrolled hypertension or bronchial asthma.
- Current use of β-blockers.
- History of chronic drug use or alcohol abuse.
- Hepatic or renal impairment.
- Known allergy to any study drug.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Metoprolol (MET)Metoprolol will be administered intravenously before anesthetic induction at the assigned dose of 0, 0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg. The study drug will be given through a dedicated intravenous catheter, and each participant will receive the dose according to the randomized treatment arm. | Drug | Metoprolol 0.1 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.1 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.1 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.1 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.1 mg/kg + Sufentanil 0.5 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.5 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.5 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.5 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.5 mcg/kg |
| SufentanilSufentanil will be administered intravenously during anesthetic induction at the assigned dose of 0.1, 0.2, 0.3, 0.4, or 0.5 mcg/kg. Each participant will receive sufentanil in combination with the assigned metoprolol dose according to the randomized treatment arm. | Drug | Metoprolol 0 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0 mg/kg + Sufentanil 0.5 mcg/kg, Metoprolol 0.1 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.1 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.1 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.1 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.1 mg/kg + Sufentanil 0.5 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.2 mg/kg + Sufentanil 0.5 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.3 mg/kg + Sufentanil 0.5 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.4 mg/kg + Sufentanil 0.5 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0.5 mg/kg + Sufentanil 0.5 mcg/kg |
| Normal Saline (0.9% NaCl)Normal saline (0.9% NaCl) will be administered intravenously before anesthetic induction as placebo in a volume matched to the metoprolol intervention. The study drug will be delivered through a dedicated intravenous catheter, and participants assigned to the placebo arm will receive a volume corresponding to the randomized dosing schedule used in the metoprolol groups. | Drug | Metoprolol 0 mg/kg + Sufentanil 0.1 mcg/kg, Metoprolol 0 mg/kg + Sufentanil 0.2 mcg/kg, Metoprolol 0 mg/kg + Sufentanil 0.3 mcg/kg, Metoprolol 0 mg/kg + Sufentanil 0.4 mcg/kg, Metoprolol 0 mg/kg + Sufentanil 0.5 mcg/kg |
Primary outcome
Percentage of participants achieving hemodynamic stability after tracheal intubation
Time frame: within 0-10 min after intubation
4 secondary outcomes
incidence of bradycardia
Time frame: within 0-10 min after intubation
incidence of tachycardia
Time frame: within 0-10 min after intubation
incidence of hypotension
Time frame: within 0-10 min after intubation
incidence of hypertension
Time frame: within 0-10 min after intubation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2026.
- Individual participant dataSharing planned: No
Related trials for General Anesthesia; Tracheal Intubation
Recruiting
Hyperangulated vs. Macintosh Style Blades for Intubation in Obstetric Patients
Obstetric, Cesarean Birth
Not yet recruitingObservational study
Modified El-Ganzouri Risk Index for Predicting Difficult Intubation in Obese Patients
Difficult Intubation, Obesity
RecruitingPhase 3
Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults
Neuromuscular Blockade
RecruitingPhase 4
Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation
Tracheal Intubation, Video Laryngoscopy
Recruiting
Video Versus Direct Laryngoscopy for Tracheal Intubation in Pediatric Surgery
Tracheal Intubation, Videolaryngoscopy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yanhua Guo principal investigator
Fujian Provincial Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Metoprolol (MET), Sufentanil and Normal Saline (0.9% NaCl) in people with General Anesthesia; Tracheal Intubation, run by Fujian Provincial Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yanhua Guo (+86-18050333902, guoyanhua19@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of participants achieving hemodynamic stability after tracheal intubation (time frame: within 0-10 min after intubation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2026.